Overview

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

Status:
Recruiting
Trial end date:
2025-03-05
Target enrollment:
Participant gender:
Summary
Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Yake Biotechnology Ltd.